METHOTREXATE
X-Linked Lymphoproliferative Syndrome
Fairview University Medical CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the X-Linked Lymphoproliferative Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Thiotepa University of Florida | Phase 2 | BB |
Cytosin-Arabinosid Baylor College of Medicine | Phase 2 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Fludarabine Washington University School of Medicine | Phase 2 | CCC |
Evomela Washington University School of Medicine | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
METHOTREXATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →